
Piramal Pharma receives USFDA EIR for US facility; inspection closed with VAI
Piramal Pharma gets USFDA EIR with VAI for its Lexington plant, closing the 2025 inspection, shares edge up though stock remains 34% down over the…

Piramal Pharma gets USFDA EIR with VAI for its Lexington plant, closing the 2025 inspection, shares edge up though stock remains 34% down over the…

Maulik Patel, Head of Research, Equirus Investment Securities, said growth in CNG volumes is slowing, especially in key markets like Delhi. Policy reforms such as…

Paytm’s sharp focus on digitizing SME merchants improved monetization capability, thereby driving strong revenue growth, Haitong said, adding that there are structural levers in play…

US inflation rose in March due to higher energy prices, while consumer confidence weakened and GDP growth slowed. Economists say the impact on household income…

On competition, Goldman Sachs expects Blinkit to continue gaining share from Swiggy, but acknowledged that growth may have been impacted in recent months due to…

Rupee opens sharply weaker at 93.28 per dollar as crude jumps and risk aversion rises, Trump Hormuz blockade warning lifts oil, analysts see continued rupee…

Emkay wrote in its note that with a forward price-to-earnings valuation of 70 times, the stock is pricing in a business that DMart needs to…

JPMorgan wrote in its note that the system mortgage should grow between 8% – 10% over the next three to five years, which has come…

The changes are seen as positive for M&M and Hyundai, as meeting CAFE norms now appears easier and less of a risk. These companies are…

Under the current rules, Tata Sons is classified as an upper-layer NBFC, which mandates it to list by September 30,2025. Tata Sons is in fact,…